esomeprazole

Phase 3Terminated

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Nausea

Conditions

Nausea

Trial Timeline

Aug 1, 2005 → Feb 1, 2012

NCT ID

NCT00206440

About esomeprazole

esomeprazole is a phase 3 stage product being developed by AstraZeneca for Nausea. The current trial status is terminated. This product is registered under clinical trial identifier NCT00206440. Target conditions include Nausea.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01370538	Phase 3	Completed	Aug 1, 2011	Oct 1, 2011	Heartburn
NCT01370525	Phase 3	Completed	Aug 1, 2011	Oct 1, 2011	Heartburn
NCT00474019	Phase 1	Completed	Oct 1, 2007	Oct 1, 2009	Pharmacokinetics
NCT00427635	Phase 3	Completed	Oct 1, 2006	Apr 1, 2009	GERD
NCT00384592	Approved	Completed	Sep 1, 2006	May 1, 2007	Gastro-Oesophageal Reflux Disease
NCT00318968	Approved	Completed	May 1, 2006	Nov 1, 2007	GERD
NCT00608712	Approved	Completed	Nov 1, 2005	Aug 1, 2006	Postoperative Bariatric Surgery
NCT00251979	Phase 3	Completed	Oct 1, 2005	Dec 1, 2007	Gastrointestinal Hemorrhage
NCT00392002	Approved	Completed	Oct 1, 2005	May 1, 2007	Gastroesophageal Reflux
NCT00242736	Approved	Completed	Oct 1, 2005	Jan 1, 2006	GERD
NCT00291746	Approved	Completed	Sep 1, 2005	Nov 1, 2006	Gastroesophageal Reflux
NCT00206440	Phase 3	Terminated	Aug 1, 2005	Feb 1, 2012	Nausea
NCT00243724	Phase 3	Completed	Apr 1, 2005	Jun 1, 2007	Gastroesophageal Reflux
NCT00524251	Pre-clinical	Completed	Jun 1, 2004	Mar 1, 2008	GERD
NCT00251966	Phase 3	Completed	May 1, 2004	Sep 1, 2005	Gastroesophageal Reflux
NCT00251901	Phase 3	Completed	May 1, 2004	Jul 1, 2005	Chest Pain
NCT00120315	Approved	Completed	Dec 1, 2003	Mar 1, 2007	Dyspepsia
NCT00574925	Approved	Completed	Nov 1, 2003	Oct 1, 2007	Gastroesophageal Reflux Disease (GERD)
NCT00222131	Phase 2	Completed	Oct 1, 2003	Jan 1, 2008	Indigestion
NCT00318084	Approved	Completed	Jan 1, 2003	—	GERD

Competing Products

20 competing products in Nausea

See all competitors

Product	Company	Stage	Hype Score
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IV	Eisai	Approved	85
Sancuso + IV granisetron	Kyowa Kirin	Phase 1	33
granisetron transdermal system + Granisetron IV	Kyowa Kirin	Phase 1	33
palonesetron	Eisai	Phase 2	52
Ondansetron + Palonosetron	Eisai	Phase 2	52
Granisetron	Kyowa Kirin	Phase 3	77
Sancuso + IV granisetron	Kyowa Kirin	Phase 1	33
Droperidol	Kyowa Kirin	Approved	85
LY3537021 + Placebo + Standard of Care Antiemetic Therapies + Background Chemotherapy	Eli Lilly	Phase 2	52
Rolapitant Dose 1 + Rolapitant Dose 2 + Rolapitant Dose 3 + Rolapitant Dose 4 + Ondansetron + Placebo	Merck	Phase 2	52
Fosaprepitant dimeglumine + Fosaprepitant Placebo + Dexamethasone + Ondansetron + Dexamethasone Placebo + Ondansetron Placebo + Rescue Therapy	Merck	Phase 3	77
Aprepitant + Aprepitant Placebo + Ondansetron + Dexamethasone + Ondansetron Placebo + Rescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride).	Merck	Approved	85
Dexamethasone + Aprepitant + Placebo Dexamethasone	Merck	Pre-clinical	23
Comparator: MK0517 + Comparator: ondansetron	Merck	Phase 3	77
Aprepitant, Dexamethasone, Ondansetron + Aprepitant, Dexamethasone, Placebo	Merck	Approved	85
Fosaprepitant	Merck	Phase 2	52
Fosaprepitant + Placebo for fosaprepitant + Ondansetron + Dexamethasone + 5-HT3 antagonist	Merck	Phase 3	77
Aprepitant + Scopolamine	Merck	Pre-clinical	23
Fosaprepitant + Dexamethasone + 5HT3	Merck	Phase 2	52
aprepitant + Comparator: Placebo to aprepitant + dexamethasone + granisetron + dexamethasone	Merck	Phase 3	77

Other Products from AstraZeneca

QuetiapineApproved

Dapagliflozin 5 mg + Placebo tabletApproved

QuetiapineApproved

Ticagrelor + ClopidogrelApproved

DurvalumabApproved